Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Feature|Articles|August 7, 2025
Top 5 benign urology headlines you missed in July 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.
Advertisement
Advertisement
There was a wealth of important developments across urology in July 2025, with notable advancements in benign conditions such as stress urinary incontinence (SUI) and benign prostatic hyperplasia (BPH).
Related to this article
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Advertisement
Advertisement